Ebpay生命医药出版社

    Ebpay生命

    100205

    论文已发表

    提 交 论 文


    注册即可获取Ebpay生命的最新动态

    注 册



    IF 收录期刊



    • 3.3 Breast Cancer (Dove Med Press)
    • 3.4 Clin Epidemiol
    • 2.5 Cancer Manag Res
    • 2.9 Infect Drug Resist
    • 3.5 Clin Interv Aging
    • 4.7 Drug Des Dev Ther
    • 2.7 Int J Chronic Obstr
    • 6.6 Int J Nanomed
    • 2.5 Int J Women's Health
    • 2.5 Neuropsych Dis Treat
    • 2.7 OncoTargets Ther
    • 2.0 Patient Prefer Adher
    • 2.3 Ther Clin Risk Manag
    • 2.5 J Pain Res
    • 2.8 Diabet Metab Synd Ob
    • 2.8 Psychol Res Behav Ma
    • 3.0 Nat Sci Sleep
    • 1.8 Pharmgenomics Pers Med
    • 2.7 Risk Manag Healthc Policy
    • 4.2 J Inflamm Res
    • 2.1 Int J Gen Med
    • 4.2 J Hepatocell Carcinoma
    • 3.7 J Asthma Allergy
    • 1.9 Clin Cosmet Investig Dermatol
    • 2.7 J Multidiscip Healthc



    更多详情 >>





    公司动态

    Ebpay生命医药出版社最新文章精选 (Part 3)

     

    Ebpay生命医药出版社专门从事开放获取同行评议期刊的出版业务,这些期刊广泛地涉及科学、技术特别是医药领域。Ebpay生命旗下共有 130 多种开放获取期刊，许多优秀医药论文已经在我们的中文网站上发表。我们特意摘选了一些论文，与大家一起分享：


    共轭的树枝状聚合物及超声波介导的透皮双氯芬酸药物输送系统

    The purpose of the present study was to develop a novel transdermal drug-delivery system comprising a polyamidoamine dendrimer coupled with sonophoresis to enhance the permeation of diclofenac (DF) through the skin. The novel transdermal drug-delivery system was developed by using a statistical Plackett–Burman design.

    Hairless male Wistar rat skin was used for the DF-permeation study. Coupling media concentration, ultrasound-application time, duty cycle, distance from probe to skin, and a third-generation polyamidoamine-dendrimer concentration were selected as independent variables, while in vitro drug release was selected as a dependent variable. Independent variables were found to be statistically significant (P <0.05).

    DF gel without dendrimer and ultrasound treatment to skin (passive delivery, run 13) showed 56.69 µg/cm    2 cumulative drug permeated through the skin, while the DF-dendrimer gel without sonophoresis treatment (run 14) showed 257.3 µg/cm2 cumulative drug permeated through the skin after 24 hours. However, when the same gel was applied to sonophoresis-treated skin, drastic permeation enhancement was observed.

    In the case of run 3, the cumulative drug that permeated through the skin was 935.21 µg/cm    2. It was concluded that dendrimer-coupled sonophoresis-mediated transdermal drug delivery system has the potential to enhance the permeation of DF through the skin.



    CD20 纳米抗体梳的构建及其抗淋巴瘤作用研究


    利妥昔单抗（Rituximab, RTX）是一种针对人CD20 抗原的人-鼠嵌合型单克隆抗体，其出现大大提高了淋巴瘤的治疗效果。然而，并非所有的患者对利妥昔单抗的治疗都有较好的反应，且随着治疗的深入，越来越多的患者逐步表现出对其治疗的耐药，这大大限制了利妥昔单抗的临床应用。

    现在的研究表明，利妥昔单抗主要顺利获得以下四种机制来杀伤肿瘤细胞——补体依赖的细胞毒作用(CDC), 抗体依赖的细胞介导的细胞毒作用(ADCC),Caspase 依赖的凋亡以及溶酶体介导的程序性死亡(PCD)。然而，迄今为止尚没有一种靶向 CD20 的单克隆抗体或者抗体衍生物能够同时激活这四种机制。本研究应用纳米医学技术，将两种不同类型的 CD20 抗体（I 型抗体利妥昔单抗，II 型抗体托西莫单抗）用聚乙烯亚胺（PEI）载体进行交联，成功制备出一种新型的针对人CD20 抗原的纳米抗体梳 PPRT。

    与游离的单克隆抗体相比，PPRT 纳米抗体梳对淋巴瘤细胞表面 CD20 抗原拥有相当的结合能力和更低的解离能力。随后的研究结果表明，该纳米抗体梳能够顺利获得“细胞内交联”和“跨细胞交联”同时激活上述与 CD20     抗体相关的杀伤肿瘤细胞的所有四条通路。体内研究结果表明，PPRT 纳米抗体梳具有比游离 CD20 抗体更慢的清除率和更长的半衰期，在体内外研究中显示出极强的淋巴瘤杀伤效果。